SOX2 and small cell lung carcinoma: In this study of 238 SCLC patients, we observed survival advantages, but surprisingly only in the ten percent of patients known to have antibodies against ANNA-1/HuD (n = 23, 13.0 months, P = 0.037), or in the twelve per cent of patients with uncharacterised ANNA (ANNA-U; n = 28, 15.0 months, P = 0.0048), and not in those who tested positive for other neuronal targets (even including the strongly LEMS-associated [26] SOX2 (n = 56)), or with non-neuronal ANA (n = 24).